Profile cover photo
Profile photo
Rheumatology Network
462 followers -
Comprehensive and authoritative clinical information about rheumatoid arthritis, osteoarthritis, gout, lupus, vasculitides, juvenitle arthritis, spondyloarthritis, and other autoimmune and inflammatory conditions. l conditions.
Comprehensive and authoritative clinical information about rheumatoid arthritis, osteoarthritis, gout, lupus, vasculitides, juvenitle arthritis, spondyloarthritis, and other autoimmune and inflammatory conditions. l conditions.

462 followers
About
Rheumatology Network's posts

Post has attachment
Dealing With the Information Firehose, Part 2.

Suleman Bhana MD shares his favorite apps for storing, retrieving, and reading online journal articles. Get out from under the deluge!

http://www.rheumatologynetwork.com/rheumatic-diseases/dealing-info-firehose-part-2-reading-and-bookmarking-apps?cid=G

Post has attachment
From AAOS2015: Steroid injections hasten hip joint degeneration. http://www.rheumatologynetwork.com/aaos-2015/steroid-injections-may-hasten-hip-joint-degeneration
Photo

Post has attachment
Can treating periodontal disease modify the course of rheumatoid arthritis? An oral surgeon and a rheumatologist consider the evidence in separate reviews. http://www.rheumatologynetwork.com/rheumatoid-arthritis/update-two-hit-model-ra-two-perspectives?cid=G
Photo

Post has attachment
#RheumJC in a Nutshell: The March 3 Twitter Conversation Compiled

Did you have to miss the second Twitter-based rheumatology journal club on March 3? We've reworked the conversation in 11 easy-to-read slides.

The subject was a follow-up of the landmark RAVE study, examining the use of rituximab for relapses of ANCA-associated vasculitis. See http://www.rheumatologynetwork.com/vasculitis/rheumatology-journal-club-2-rituximab-aav-relapse?cid=G

Post has attachment
Why did a Miami rheumatologist give away $1M to help others in his specialty practicing in the community? Learn what's behind the Norman B. Gaylis award, and what the donor hopes it will accomplish.

See http://www.rheumatologynetwork.com/rheumatic-diseases/good-news-community-rheumatologists-your-own-research-grant
Photo

Post has attachment
One doctor's $1M gift to rheumatologists practicing in the community:

Norman B. Gaylis MD describes why he is giving his money away for a new research grant, and what he hopes will come of it.

Post has attachment
The FDA has approved the first US biosimilar: another form of the cancer drug Neupogen. http://www.rheumatologynetwork.com/rheumatic-diseases/fda-approves-neupogen-biosimilar-first-us

The biologic infliximab may be close on its heels.

Will this make any real difference in rheumatology? European rheumatologist Lothar Kirsch has his doubts. (See http://www.rheumatologynetwork.com/rheumatoid-arthritis/infliximab-biosimilars-launch-europe-so-what )

Post has attachment
FDA has approved first US biosimilar: Sandoz biosimilar to Amgen Neupogen (filgastrim) for AML, chronic neutropenia, patients on myelosuppressive chemotherap, cancer patients undergoing bone marrow transplant.

Post has attachment
Rheumatologists! Are you and your patients speaking different languages when it comes to medication risks?

A new study shows that they may not be hearing, or may be misinterpreting, what you say about adverse event risks. And this may have an impact on drug efficacy.

See "How Risky Conversations Fail for Rheumatologists" at http://www.rheumatologynetwork.com/rheumatoid-arthritis/how-risky-conversations-fail-rheumatologists
Photo

Post has attachment
Interleukin inhibitors for psoriasis and psoriatic arthritis: The basics in brief.

See our latest slide shown on RheumNet, sourced from a recent review by Philip Mease MD (with hyperlinks to full articles).

Bookmark and enjoy! 

http://www.rheumatologynetwork.com/psoriatic-arthritis/interleukin-inhibitors-brief
Photo
Wait while more posts are being loaded